Trelegy Ellipta is an inhaler used every day to control COPD and asthma in adults. It mixes three medicines: one calms swelling in the airways and two help the airways stay open. It is not a rescue inhaler for sudden breathing trouble.
Every report comes from a Lived member, sent anonymously.
Have you tried Trelegy Ellipta (Fluticasone Furoate / Umeclidinium / Vilanterol) for COPD?
Trelegy Ellipta is a once-daily inhaler that combines three long-acting medicines in a single device: fluticasone furoate, an inhaled corticosteroid; umeclidinium, an anticholinergic bronchodilator; and vilanterol, a long-acting beta2-agonist (LABA). It is approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), the long-term lung disease that includes emphysema and chronic bronchitis, and of asthma in adults aged 18 and older. "Maintenance" means it is used every day to keep breathing more stable and to lower the chance of flare-ups, not to relieve sudden symptoms. It is not a rescue inhaler. Anyone using it also needs a fast-acting rescue inhaler, such as albuterol, for breathing trouble that comes on suddenly. It is usually considered when one or two inhaled medicines have not been enough. In COPD, the main studies involved people who still had flare-ups despite treatment. In asthma, it was studied in adults whose symptoms were not controlled on an inhaled steroid plus a LABA. Putting all three medicines in one inhaler means one dose a day instead of two or more separate inhalers.
COPD and asthma both narrow the airways, partly because the muscle around them tightens and partly because their lining becomes inflamed and swollen. Each ingredient in Trelegy targets one part of that problem. Umeclidinium blocks acetylcholine, a nerve signal that tells the airway muscle to contract. Vilanterol works by a different route: it stimulates beta-2 receptors on the same muscle, which tells it to relax. Using both bronchodilators together opens the airways more than either one alone, and both last long enough to be taken once a day. Fluticasone furoate is a corticosteroid that calms inflammation in the airway lining. Its exact effect in COPD and asthma is not fully understood, and it does not open the airways right away. Over time it helps reduce swelling and the flare-ups that inflammation drives, which is why the steroid part matters most for preventing attacks rather than for day-to-day breathlessness.
Trelegy is a dry powder inhaler. The dose is one inhalation once a day, taken at about the same time each day. It should never be used more than once in 24 hours, even on a bad day, because extra doses do not work as a rescue and can cause side effects such as a racing heart. It comes in two strengths, written as micrograms of each ingredient in the order fluticasone furoate/umeclidinium/vilanterol: 100/62.5/25 and 200/62.5/25. Only the 100 strength is approved for COPD. For asthma, the prescriber chooses a starting strength based on how severe the asthma is and the steroid dose the person was using before; the 200 strength contains more steroid and is the maximum dose. After each dose, rinse your mouth with water and spit it out without swallowing. This lowers the chance of thrush, a yeast infection in the mouth and throat caused by steroid powder left behind. Asking a pharmacist, nurse or respiratory therapist to watch you use the inhaler is worthwhile, since the medicine only helps if the powder is actually breathed in. Keep a rescue inhaler such as albuterol with you for sudden symptoms. If you used albuterol regularly every day before starting Trelegy, the usual plan is to switch to using it only when needed.
Common side effects include colds and other upper respiratory infections, sore throat, headache, back pain, hoarseness and a changed sense of taste. Thrush shows up as white patches or soreness in the mouth or throat; it is treated with an antifungal and usually does not require stopping Trelegy. Pneumonia is more common in people with COPD who use inhaled steroids. In a year-long COPD study, pneumonia occurred in 8% of people on Trelegy, 7% on a steroid plus LABA inhaler and 5% on a two-bronchodilator inhaler without a steroid. Because pneumonia and a COPD flare-up can look alike, contact the care team about fever, chills, a worsening cough or a change in the color of your mucus. Contact the prescriber right away, and stop using Trelegy until you have spoken with them, if wheezing, coughing or chest tightness gets worse right after a dose, since the inhaler can rarely tighten the airways instead of opening them. The same prompt contact applies to a pounding or fast heartbeat, chest pain or marked shakiness; to eye pain, blurred vision, or halos around lights with red eyes (signs of a glaucoma attack); and to difficulty passing urine or painful urination. Swelling of the face, lips, tongue or throat, or trouble breathing with hives after a dose, can be a severe allergic reaction and needs emergency care. Needing your rescue inhaler more often than usual, or finding that it helps less, is a sign that COPD or asthma is getting worse and needs prompt medical attention.
Trelegy should not be combined with any other inhaler that contains a long-acting beta-agonist, such as salmeterol, formoterol or vilanterol in another product, because doubling up can cause an overdose with heart effects. It should also not be paired with another anticholinergic medicine, including other long-acting anticholinergic inhalers, because side effects add up. When Trelegy replaces earlier maintenance inhalers, confirm which ones to stop. Other medicines that need a prescriber's review include beta-blockers (blood pressure and heart drugs that can block vilanterol and tighten the airways); certain antidepressants called monoamine oxidase (MAO) inhibitors and tricyclics, and other drugs that affect heart rhythm; non-potassium-sparing diuretics, or water pills, which can lower potassium further; and medicines that strongly block the liver enzyme that breaks down the steroid and vilanterol, such as the antifungal ketoconazole, which can raise their levels in the blood. People with a severe milk protein allergy should not use Trelegy, because the powder contains lactose (milk sugar), and severe allergic reactions have been reported in people with this allergy after using similar lactose-containing powder inhalers. Tell the prescriber about heart disease or rhythm problems, narrow-angle glaucoma, an enlarged prostate or bladder problems, osteoporosis, diabetes, seizures, an overactive thyroid, or any current infection, including tuberculosis. Steroids can make chickenpox or measles more serious in someone who is not immune, so an exposure is worth reporting promptly. Anyone moving from steroid tablets to Trelegy needs a slow, supervised taper, because the body's own steroid production can take time to recover.
The two bronchodilators start working quickly; in studies, lung function measurements improved within the first day. The steroid's protective effect builds more gradually, and the main payoff, fewer flare-ups, is judged over months. A moderate flare-up is one that needs steroid tablets or antibiotics, and a severe one leads to hospital care. In a year-long study of people with COPD who had at least one flare-up in the previous year, those using Trelegy had about 15% fewer moderate or severe flare-ups than people on a steroid plus LABA inhaler, and about 25% fewer than people on two bronchodilators without a steroid. On average, that was a little under one flare-up a year compared with a little over one. In adults with poorly controlled asthma, adding umeclidinium improved breathing tests but did not significantly reduce asthma attacks; the higher steroid dose mainly reduced attacks, particularly in people with signs of allergic-type airway inflammation. Trelegy is generally a long-term medicine, used every day even when breathing feels good. Stopping it without a plan can let symptoms return. Follow-up visits usually review flare-ups, rescue inhaler use and inhaler technique. In asthma, a person who is not controlled on the lower strength may move to the higher one; for COPD, the dose stays the same. With long-term use, regular eye exams for glaucoma and cataracts are reasonable, and people at risk of weak bones may need their bone density checked.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Trelegy Ellipta (Fluticasone Furoate / Umeclidinium / Vilanterol), what you've noticed, or ask the community a question.